39.69 +0.04 (0.11%)
After hours: 4:08PM EDT
|Bid||39.64 x 1400|
|Ask||39.65 x 3200|
|Day's range||39.31 - 39.92|
|52-week range||29.99 - 43.08|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||23.23|
|Earnings date||26 Jul 2021 - 30 Jul 2021|
|Forward dividend & yield||1.56 (3.90%)|
|Ex-dividend date||06 May 2021|
|1y target est||40.84|
Dr. Jonathan Javitt, CEO of NeuroRX & adjunct professor at Johns Hopkins School of Medicine, joined Yahoo Finance to discuss the latest on covid-19.
Pfizer (NYSE: PFE) just scored another first. The U.S. Food and Drug Administration (FDA) granted it authorization for the use of its coronavirus vaccine in a new age group -- 12 through 15. In December, Pfizer became the first company to win Emergency Use Authorization (EUA) for a coronavirus vaccine.
Here's how a drug discovery company and a coronavirus vaccine drugmaker can boost investors' portfolios.